Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.43 USD | +1.72% | +6.40% | -45.35% |
05-08 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
05-08 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.35% | 636M | |
+29.26% | 682B | |
+30.81% | 586B | |
-2.95% | 364B | |
+17.78% | 327B | |
+4.10% | 285B | |
+16.26% | 240B | |
+9.91% | 209B | |
-8.34% | 203B | |
+7.96% | 165B |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating